Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hill Street drives brand interest and awareness with national alcohol-free promotion
Hill Street drives brand interest and awareness with national alcohol-free promotion
Canada NewsWire
TORONTO, March 4, 2019
TORONTO, March 4, 2019 /CNW/ - The Hill Street Beverage Company (TSXV: BEER) ("Hill Street" or the "Company") challenged Canadians to go alcohol-free for the month of January, and in doing so demonstrated its ability to leverage effective marketing to achieve its business objectives.
The "Hill Street Challenge" represented the Company's first fully-integrated marketing campaign, and capitalized on a growing trend to go "dry" for the month of January. It was designed to build awareness of the Hill Street brand amongst Canadians, help people understand the benefits of going alcohol-free, and ultimately drive consideration of the company's alcohol-free products.
"We created the Hill Street Challenge as a way to highlight some benefits of going alcohol-free, but decided to do that in a slightly outrageous way so people would sit-up and take notice" said David Pullara, Chief Marketing Officer at Hill Street, referring to the irreverent videos created as part of the campaign. "We've been working hard over the past year to get people to understand that giving up alcohol doesn't mean giving up drinking or even having a good time, and the outstanding results of this campaign demonstrate our efforts are having an impact."
The Hill Street Challenge was supported using a number of creative elements; video ads, digital and performance marketing assets, and radio partnerships with Zoomer Media, Humble & Fred Radio, and WhatSheSaid Talk Radio were all used to drive awareness of the Challenge.
The Hill Street Challenge also involved a contest component where people were asked to use social media to help one of Hill Street's not-for-profit medical research partners -- either Arthritis Society or Prostate Cancer Canada -- earn a $10,000 donation, resulting in over 800 social media posts. At the end of the campaign, Prostate Cancer Canada earned the $10,000 donation, but a $2,500 donation was also awarded to Arthritis Society for their efforts. Prostate Cancer Canada President and CEO Peter Coleridge was quick to praise the initiative. "We're thrilled to win the Hill Street Challenge," he said. "The initiative raised awareness for two important diseases affecting Canadians – prostate cancer and arthritis. Hill Street Beverage Company is an incredible partner and the gift resulting from our challenge win will allow us to continue to help Canadian families facing this disease through research, support services and education tools."
The Hill Street Challenge generated over 6 million impressions across social media, and over 2.1 million people viewed the video content. The click-through rate from the videos to the Hill Street Challenge landing page was 1.45%, almost seven times the North American average of 0.21%.1 This drove an 8,400% increase in web traffic versus the 30-days prior to the campaign's launch, with the majority of traffic coming from first-time visitors.
Hill Street's marketing is design ed to build the Hill Street brand in advance of October, when cannabis-edibles are expected to become legal in Canada. The Company plans to introduce its cannabis-infused beverages under the Hill Street name, leveraging awareness of its alcohol-free adult beverages. A survey conducted in early February of 1,582 Canadians indicated a 300% increase in awareness of "Hill Street" amongst adults, and a 450% increase amongst millennials, over the past eight months.
About Hill Street Beverage Company Inc. (TSXV: BEER)
Hill Street Beverage Company is the world's most award-winning company exclusively focused on alcohol-free beer, wine, and adult format beverages. Hill Street's great-tasting products include Hill Street Craft Brewed Lager, Designated Draft alcohol-free beer, Vin(Zero) wines, and Vintense wines, and have won numerous medals and accolades including three Gold, two Silver, and two Bronze Medals at the U.S. Open Beer Cha mpionships, the Retail Council of Canada's Grand Prix award, and a prestigious Double Gold Medal at the San Francisco International Wine Challenge. Hill Street will also produce and sell cannabis-infused adult beverages as soon as the sale of cannabis edibles becomes legal in Canada, expected to occur by October 17, 2019. Hill Street has licensed a patented infusion technology from Lexaria Bioscience (CSE:LXX) that allows cannabis to be infused into a beverage such that it mimics the onset and duration effects of alcohol with minimal impact on the taste, smell, or shelf-stability of the product. Check out Hill Street's award-winning line-up and order product to be delivered straight to your home at www.hillstreetbeverages.com.
1 Source: "Video Ad Performance Metrics, North America", Extreme Reach, October 2018, via eMarketer.com
SOURCE Hill Street Beverage Co.
Looks like we're marking out a bullish flag pattern after that nice run up from .80.
Shhhhhhh! It's a secret.
Weird, I don't know how much they're paying network newswire but it's too much!
I do disagree with Silky on one point-clinical trials will cost 100 million.
Nicotine is not a new drug nor is it being tested for its efficacy against a certain disease or condition, therefore I believe that a full set of clinical trials will not be necessary. Human toxicity tests should be all that is necessary before approval to market this oral nicotine product. If the product doesn't cause stomach problems or harm the liver they should be good to go. IMHO
They sell a gum, a mist and a lozenge as well as the patch.
None of the oral products are meant to be swallowed as nicotine can cause stomach upset. Dissolve in mouth and nicotine is absorbed through membranes.
https://www.nicorette.ca/how-to-quit-smoking/find-the-best-way-to-quit-smoking-for-you
I don't have any idea what clinical trials will be needed and how long they may take.
DehydraTECH has one big advantage over competitors. It's natural. Here's a list of the ingredients for Nicorette Spray Mist. You gotta love that Butylated hydroxytoluene, man that's nasty stuff!
Propylene glycol
Anhydrous ethanol
Trometamol
Poloxamer 407
Glycerol
Sodium hydrogen carbonate
Levomenthol
Mint flavour
Cooling flavour
Sucralose
Acesulfame potassium
Butylated hydroxytoluene
Hydrochloric acid
Purified water
From Silky_Johnson on Stockhouse:
Altria, Cronos, Lexaria?!
I’ve been a shareholder of both Cronos & Lexaria for a couple of years now...Cronos has been doing fantastically since the partnership with Altria whereas Lexaria’s marquis deal has not been accurately recognized by the market...
1) While the R&D commitment of Altria seems to be a nominal amount, the deal seems to suggest that Altria will be responsible for the commercializations of the products that Lexaria has helped formulate. This would require an FDA submission and will likely cost over $100 million dollars before the first product is sold.
For an Altria commitment of that magnitude (on top of the $12 million to Lexaria in the terms of the offer) they will not have a majority stake in Lexaria Nicotine until/if they buy the subsidiary.
Conclusion...we have a non-dilutive financing of a product suite that will likely generate billions of dollars in revenue a couple years down the road. This is what the market is missing...
Another thing...I scrolled through the 8-k today of the contract between Altria & Lexaria. See below for some rather revealing details that no one is picking up on...
1.3 “Ancillary Product” means an Unlicensed Product that contains a cannabinoid or other bioactive material derived from Cannabisas the Other Active.
6.2 (f) Licensor understands and acknowledges that the Licensee’s participation in the development of Improvements, by funding or otherwise, including pursuant to work conducted under the Warrant and Option Agreement, is subject to certain obligations of Licensee regarding the research, development, marketing or other commercialization of cannabinoid-containing products and materials, pursuant to an agreement between Licensee or its Affiliates with a Third Party (the “Third Party Partner”) as of the Effective Date, insofar as such Improvements relate to Ancillary Products.
6.2(f) parts (i) and (ii) with respect to Lexaria's ability to apply any business improvements beyond nicotine pursuant to Altria’s right of first negotiation to apply same to its Third Party Partner.
Third party partner...Cronos?!?! Everything is is in the writing and I think we will likely see Cronos and Lexaria partner together for edible (potential beverage) formulations.
Regardless, it seems as if Altria is keen on using Lexy for more than just Nicotine!
Cronos may also go after Hill Street who is of course licensing DehydraTECH
Either way, I think Lexy is the best ancillary play out there and if I’m right, it is an absolute steal at these prices.
Makes one think DehydraTECH, will it work with insulin? This pill must be really expensive and only works on an empty stomach!
https://futurism.com/mit-insulin-pill-stomach-diabetes
Other pills are in development.
https://www.diabetes.co.uk/insulin/insulin-pill.html
You know what I mean! Tell him that shareholders are seeking more/better communication. That's not a lot to ask, good communication is a necessary management skill. The problems at LSU are well documented, I don't think anyone blames John for that government boondoggle! What's happening with Teco etc?
Tell him to communicate! Shareholders deserve better!
I don't believe it either. I was trying to find an e-mail address for the author to send her a link to Lexaria, but they don't give addresses. Maybe someone could hit them up on Twitter, I don't do Twitter.
What does this have to do with GB Sciences? Please post on Nanosphere board.
Yes, but that's just the first test. Now the product needs further processing and then will have to be submitted for government testing again, before it can be sold to patients. And there are only 14 pounds of flower to be processed into medicinal products for all of Louisiana.
Sure Just Accusations!
https://www.cannabistech.com/articles/fohse-surpassing-the-sun/
Fohse: Surpassing The Sun
As James Bradley and his associates ended one project in Las Vegas, they were left seeking a new opportunity. With a philosophy that perfection is not a destination, but a journey – he and his team set out to revolutionize LED lighting systems and join the momentum in a budding industry.
KRISTINA ETTER
Before becoming a freelance cannabis writer, Kristina Etter, spent 20 years in corporate information technology with companies including Maytag Appliances, Wells Fargo Financial, and DuPont Pioneer. With a niche in mobile technology and…
Shortly before Nevada voted in adult, recreational cannabis, James Bradley and his colleagues, Brett Stevens, and Ben Arnet started vetting a wide range of entrepreneurial opportunities within the industry including opening a retail shop, building a new cultivation facility or retrofitting an old one, they even sorted through a number of ancillary services. However, when company president, Arnet received word from an old school friend, their future became much brighter, literally.
CannabisTech caught up with Bradley, Chief Marketing Officer of Fohse, this week in a phone interview to discuss the launch of his company and their innovative new LED lighting system which is set to disrupt the cannabis lighting market in early 2019.
Avoiding The LED Graveyard
The high school friend who reached out to Arnet was Alex Gerard, an engineer with experience working for technology giants such as Boston Scientific and Medtronic. Additionally, he had been working on a side project designing an LED light specifically for cannabis. Although Alex was confident in his design, he needed their expertise in business to bring the idea to life. And so, a partnership formed and they started vetting the technology.
With a prototype in hand, they approached GB Sciences, a cannabis cultivation and biopharmaceutical research facility in Las Vegas. Despite having tested all other LED lighting applications, (which Bradley pointed out were all now piled in a corner in a makeshift, LED graveyard of sorts) the team at GB Sciences agreed to give Fohse LED lighting systems a chance. Bradley stated, “They put our lights in as an afterthought, but they performed very well - growing side by side with their HPS lights. At this point, we knew we had something special on our hands.”
SPEAKING THE PLANTS LANGUAGE
Many cultivators are hesitant to move to LED lighting entirely. While the energy cost savings initially looks appealing, many growers are quickly turned off by the less than stellar yields due to the lack of power. Bradley explained, “Many LED lights are designed for other types of horticulture applications. Some might be for low profile plants like strawberries, while others are designed for taller plants like tomatoes – few manufacturers designed for cannabis specifically.”
While they realized power was a significant factor in why other LEDs failed, their primary goal with their lighting system went much more in-depth. Bradley continued, “Our high-powered lights come with a spectrum which matches what we’ve learned about cannabis. Essentially, we’ve learned how to speak the plant’s language.”
Through a process called “photomorphogenesis,” plants use light to determine certain development factors. By responding to different spectrums and wavelengths of light, the plant develops accordingly. Different ratios of wavelengths help the plant to identify how long to make stems, how broad to grow their leaves, or how thick to build their roots. By manipulating the light the plants receive, growers can practically tell their plants how to grow.
Models Currently Available
While the A3i is scheduled for production starting in January, Fohse is also developing other lighting systems for deployment later in 2019.
The Flagship, A3i – this 1500 watt LED fixture has multiple spectrum modes and a PPF of 2,950 uMol/s. Designed for flowering, this fixture is already sold out for their first production run with more than 5,000 units pre-sold. ?????
The F1V – this fixture, designed for vertical applications or vegetative phases, comes in either 630 or 800 watts, providing a PPF of 1,840 uMol/s.
The O6i – Not set to hit the market until Spring, this LED fixture is designed explicitly for supplementing greenhouse lighting. Using sensor technology, this fixture actually determines whether or not your crop is getting the recommended daily light integral necessary.
Bradley mentioned the biggest advantage with Fohse LEDs is the ceramic coating used. Other LEDs use a plastic coating which basically renders the lights useless in two to three years.
THE RESULTS SPEAK FOR THEMSELVES
Shocked by the initial results, the prototype used by GB Sciences became the launch point for Fohse LED lighting. Although the company has yet to move into a full-production environment, today, the company is already sold-out on 5,000 pre-orders for their first production run of their flagship model, the A3i fixture, which is scheduled for the first quarter of 2019. Meanwhile, the F1V Vegetative lighting is also nearing production phases with more than 500 fixtures pre-sold and another 200 fixtures being installed next week in Michigan according to Bradley.
While the company is just set to launch their first production run at the beginning of the year, they anticipate much research in their future. Partnering with Christopher Sloper, who literally wrote the book on LED lighting for cannabis, they are excited to bring an added level of education and standardization to the industry.
For more information about Fohse LED lights or the company go to their website at www.fohse.com.
Thanks for the compliment, europa. No, I'm not a troll and GB's not really competing with anyone. I've been a long shareholder of GB for almost 3 years.
One thing I should make clear is that this mess at LSU is not of GB's making, it seems to be almost completely due to government incompetence. Perhaps it's time for GB to cut their losses, pull out of this deal and sue LSU and gov't for losses.
You really hurt my feelings!
14 pounds-Sickening, absolutely totally pitiful!
What's that going to give them, about 1 pound of oil?
This wouldn't even be 1 days supply for Louisiana.
Not only that, it has to be tested one more time after it's processed further and they still haven't been able to move into the main grow facility. No wonder management doesn't want to communicate with shareholders, they don't have anything good to say at all.
I wonder how bad things are at Teco, apparently, they had problems with LED lights that didn't produce the right spectrum, and they all had to be replaced at least once.
With Altria in charge, Cronos is going to be focused on non-combustible products as Altria has vowed to move completely away from combustible tobacco products, so no doubt, they will do the same with cannabis.
Altria+Cronos+Lexaria+Hill Street Beverages. A match made in heaven!
Lexy was giving out free samples at the MJBiz Conference.
Someone posted on FB that ChargD+ will soon be available online. Site is not active yet.
https://chrgdlife.com/
Or more likely, we crash support at .16 at head down to .05 cents.
If this is a "run" please make it stop! This is one of the worst performing MJ stocks on the market!
BEER: RBC picked up another 263,000 shares of our licensee today. They were grabbing everything that was on the table at the end of the day. Sure looks like they're moving the price up to where they want to do a financing.
I think your right, network news is screwed up? Wow, they're really helping out! NOT.
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (O
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery
Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An article discussing the company reads, “Lexaria Bioscience has 10 patents granted with over 50 patents pending. Four of the granted patents focus on the delivery of nicotine. The company is not partnering with the tobacco industry. However, Bunka informed that Lexaria is exploring the potential use of its DehydraTECH technology to help people stop smoking. . . . The company’s technology has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The goal for Lexaria is to put nicotine into some type of oral form to eliminate the need for inhalation and help people curb their smoking habits. DehydraTECH studies in 2018 included two animal studies that delivered pioneering results highlighting the improvements of nicotine delivery to blood plasma and across the blood-brain barrier (http://nnw.fm/4RGjQ). ”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
What's Holding Lexaria Back?
The fact that Lexaria has only received a patent for DehydraTech with CBD and not with THC!
All LPs are going to want to provide products with both cannabinoids so the lack of a patent for THC negates the chances of a licensing deal. This is probably why ChargD+ is only available with CBD and not THC also.
This patent is pending, let's hope that it is awarded soon, this would be a real game changer!
https://www.cnn.com/2018/12/07/investing/altria-cronos-investment-marijuana/index.html
New York (CNN Business)Altria hopes pot is the key to help it grow beyond its stagnant cigarette business.
Tobacco giant Altria is investing $1.8 billion in Canadian cannabis company Cronos Group. That will give Altria a 45% stake in the company, with an option for Altria to increase its stake to 55% over the next five years.
Reports of an Altria-Cronos deal first surfaced earlier this week. The decision by Altria to go ahead with an investment in Cronos shows that Altria is serious about investing in marijuana as a new growth area as sales of traditional cigarettes slow.
Altria's stock has fallen nearly 25% this year and the company is expected to report revenue growth of only about 1% this year and in 2019.
"Investing in Cronos Group as our exclusive partner in the emerging global cannabis category represents an exciting new growth opportunity for Altria," said Howard Willard, Altria's CEO, in a statement.
Shares of Altria (MO) rose 2% in early trading Friday while Cronos (CRON) soared more than 30%.
"Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth," said Cronos CEO Mike Gorenstein in a statement.
Gorenstein added that Cronos will use the investment from Altria to expand its distribution and infrastructure around the world and also boost its investments in research and development for new brands and products.
Cronos and other cannabis stocks have been thrust into the spotlight in the past few months following the legalization of recreational marijuana in Canada in October, as well as legalized recreational and medical pot in several US states last month.
With Democrats winning control of the US House, Congress may finally pass the Farm Bill, which would make it legal to produce hemp and potentially open the door for more products containing cannabidiol, or CBD.
Many alcoholic beverage, tobacco and other consumer products companies may want to bet on cannabis.
Canadian marijuana company Canopy Growth (CGC) already has received a multibillion dollar investment from Corona owner Constellation Brands (STZ).
Coca-Cola (KO) was rumored to be considering an investment in Canadian cannabis company Aurora (ACB).
Coca-Cola CEO says company has no plans for cannabis drinks
Coca-Cola CEO says company has no plans for cannabis drinks
But Coke shot down the talk in October. CEO James Quincey said the company "doesn't have any plans at this stage" to enter the CBD market.
Coke's archrival Pepsi (PEP) hasn't completely ruled out a move into cannabis. Chief Financial Officer Hugh Johnston told analysts during its earnings call in October that "it's fair to say we look at everything" in response to a question about cannabis.
The Canadian subsidiary of Molson Coors (TAP) has a joint venture with The Hydropothecary Corporation to produce cannabis-infused drinks for the Canadian market. Lagunitas, a beer brand owned by Heineken (HEINY), is selling a cannabis-infused sparkling water brand in California.
Investors seem to be betting that more deals could be coming. Shares of Canopy, Aurora, Tilray (TLRY) and Aphria (APHA) all surged Friday morning.
Lexaria Warrant Exercises
(via TheNewswire)
Kelowna, British Columbia / TheNewswire / January 25, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received funds from the exer cise of warrants.
Lexaria has received US$108,000from the exercise of 180,000 warrants at the exercise price of US$0.60 previously granted to third parties who are neither officers nor directors of the Company and has issued 180,000 common shares as a result. Lexaria has also issued 100,000 restricted common shares at an issue price of US$1.31 as required by a consulting agreement.
No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitterhttps://twitter.com/lexariacorp
and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
BEER, Hill Street Beverages
Yesterday RBC bought 984,040 and another 532,600 today.
What's happening with our licensee? Will we find out next week?
Alex Blanchard
Ablanchard@lexariabioscience.com
https://www.medicalnewstoday.com/articles/244972.php
The big disadvantage nanotechnology has to Lexaria's tech is the high cost and concerns over safety.
"However, across the range, there exist considerable challenges, the greatest of which appear to be how to scale up production of materials and tools, and how to bring down costs and timescales.
But another challenge is how to quickly secure public confidence that this rapidly expanding technology is safe. And so far, it is not clear whether that is being done."
Our licensee Hill Street Beverages (BEER) is trying to bust a move this morning. Looks like a breakout from a reverse head and shoulders bottom!
Yeah, it all makes a lot of sense. Back in Oct. Hill Street (BEER) said they were in discussions with a major LP in regards to an equity financing which they said should take place before the month end. This never happened but this was at the time Altria stepped in to negotiate an equity investment in CRON, so CRON probably had to step away. But now, one can assume they have the blessing of their new masters at Altria.
The chairman of Altria is not returning my phone calls. LOL